Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Bullboard Posts
Comment by snuff69on Jan 07, 2019 10:22am
146 Views
Post# 29194401

RE:RE:News

RE:RE:NewsHere’s what George had to say in his follow up email today 
Attached is a news release about a group of doctors in The Netherlands, who have been using the VMS to study patients with Sarcoidosis - a disease that mostly affects the lungs and puts people at risk for pulmonary hypertension.

The study will be published in a top peer-reviewed medical journal later this year, but the investigators have given us per mission to release these top-line results.

1.      20 of the 500 patients had abnormal RV shapes and pulmonary hypertension, which as you know is a very serious condition and needs to be detected early for any hope of treatment.
2.      This is the first study showing the VMS can be used to “screen" people at risk for pulmonary hypertension and find those people who have already developed the condition.
3.      There are lots of conditions that give rise to pulmonary hypertension (lung cancer, sickle-cell anemia, COPD, etc.) and so this is an exciting study.
4.      Our marketing group has identified the doctors in Europe and north America who specialize in Sarcoidosis and will now begin a campaign to make them aware of the VMS’s ability to screen their patients.  
5.      The guidelines suggest that patients should be screened every three months for signs of pulmonary hypertension, but this has been impossible as the only way to diagnose pulmonary hypertension is by cardiac catheterization, which is invasive and dangerous.
6.      We are applaud this group in the The Netherlands for such an innovative clinical study and await even more information on the ability of the VMS to monitor the progression for he disease in these patients.

Thanks for your continued support,

Regards,

George Adams, PhD, ICD.D
CEO
Ventripoint Diagnostics Ltd..
Cell: 519-803-6937

Bullboard Posts